When subcloned into low-copy-number expression vectors, rumAB, encoding polV (RumA' B), is best characterized as a potent mutator giving rise to high levels of spontaneous mutagenesis in vivo. This is in dramatic contrast to the poorly mutable phenotype when polV is expressed from the native 88.5 kb R391, suggesting that R391 expresses cis-acting factors that suppress the expression and/or the activity of polV . Indeed, we recently discovered that SetR , an ortholog of λ cI repressor, is a transcriptional repressor of rumAB. Here, we report that CroS , an ortholog of λ Cro, also serves as a potent transcriptional repressor of rumAB. Levels of RumA are dependent upon an interplay between SetR and CroS , with the greatest reduction of RumA protein levels observed in the absence of SetR and the presence of CroS . Under these conditions, CroS completely abolishes the high levels of mutagenesis promoted by polV expressed from low-copy-number plasmids. Furthermore, deletion of croS on the native R391 results in a dramatic increase in mutagenesis, indicating that CroS plays a major role in suppressing polV mutagenesis in vivo. Inactivating mutations in CroS therefore have the distinct possibility of increasing cellular mutagenesis that could lead to the evolution of antibiotic resistance of pathogenic bacteria harboring R391.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8460599 | PMC |
http://dx.doi.org/10.1111/mmi.14777 | DOI Listing |
Oncol Rep
February 2025
Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Scottsdale, AZ 85259, USA.
Targeted drugs have revolutionized the treatment of advanced non‑small cell lung cancer (NSCLC). However, the understanding of how cardiac comorbidity and toxicity affect the clinical outcomes of patients following targeted therapy remains limited. In a 14‑year cohort, cardiac comorbidities and toxicities among patients with stage‑IV NSCLC treated with targeted therapy were identified.
View Article and Find Full Text PDFClin Transl Sci
December 2024
Cytokinetics, South San Francisco, California, USA.
The human voltage-gated sodium channel Na1.5 (hNa1.5/SCN5A) plays a critical role in the initiation and propagation of action potentials in cardiac myocytes, and its modulation by various drugs has significant implications for cardiac safety.
View Article and Find Full Text PDFLancet Reg Health West Pac
December 2024
WHO Collaborating Centre for Antimicrobial Resistance, The University of Melbourne at Peter Doherty Institute for Infection and Immunity, Melbourne, Australia.
Background: Fiji is a Pacific Island nation grappling with the increasing threat of antimicrobial resistance (AMR). While genomic technologies are increasingly utilised to understand the emergence and spread of AMR globally, its application to inform outbreak responses in low- and middle-income settings has not been reported.
Methods: Through an established capacity building program, suspected carbapenem-resistant organisms (CRO) identified at Colonial War Memorial Hospital in Fiji (Jan 2022-Oct 2023) underwent whole genome sequencing and analysis.
Public Health Action
December 2024
Burnet Institute, Melbourne, Australia.
Setting: Papua New Guinea is a high-burden multidrug-resistant TB (MDR/RR-TB) country that reports low rates of bacteriological confirmation. Sputum drug susceptibility testing for second-line drugs is important. Access to culture is limited.
View Article and Find Full Text PDFBr J Surg
November 2024
Centre of Research on Inflammation (CRI), INSERM U1149, Paris, France.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!